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ABSTRAK  
 
Latar belakang: Plasma sejuk segar (fresh frozen plasma; FFP) ialah komponen darah 
yang sering dipohon oleh doktor sama ada bertujuan untuk transfusi terapeutik atau 
transfusi profilaktik. Transfusi profilaktik FFP di kalangan pesakit yang mempunyai 
masalah pembekuan darah (coagulopathy) adalah untuk mengelakkan episod pendarahan 
ketika prosedur rawatan invasif. Nilai international normalised ratio (INR) melebihi 1.50 
sering dijadikan nilai penanda bagi transfusi FFP sebelum prosedur intervensi. Kajian ini 
berhasrat untuk menilai keberkesanan transfusi FFP dalam menormalkan bacaan INR 
sebelum prosedur intervensi dijalankan dan menentukan hasil transfusi ini (perbezaan INR, 
episod pendarahan dan reaksi tindakbalas transfusi). 
 
Kaedah:  Kajian prospectif keratan rentas dijalankan dengan data daripada 81 pesakit yang 
menerima transfusi FFP sebelum prosedur intervensi selama tempoh tiga bulan (Disember 
2016 hingga Febuari 2017). Kajian ini telah dijalankan di Hospital Kuala Lumpur dan 
Pusat Darah Negara. Subjek kajian ini dipilih secara persampelan khusus di mana setiap 
pesakit yang merekodkan bacaan INR melebihi 1.50 dipilih. Data diperoleh daripada rekod 
perubatan pesakit dan diisi dalam proforma kajian. Kesemua data demografik dan klinikal 
berkaitan dengan keberkesanan transfusi FFP dicatatkan dan kemudiannya dianalisa. 
 
Keputusan: Peratusan pesakit yang mencapai nilai INR kurang daripada 1.51 selepas 
transfusi FFP adalah 30.30% (n=27) dengan seorang pesakit merekodkan bacaan INR 
 xi 
 
normal iaitu INR < 1.20. Hanya dua pesakit mengalami episod pendarahan selepas 
menjalani prosedur intervensi (seorang mengalami pendarahan major dan seorang 
mengalami pendarahan minor). Peratusan reaksi tindakbalas transfusi adalah rendah iaitu 
2.50%. Sebahagian besar pesakit menjalani prosedur intervensi dengan bacaan INR 
melebihi 1.50 selepas transfusi FFP (n=52) tanpa mengalami episod pendarahan. 
Keseluruhannya, transfusi FFP merekodkan perbezaan median INR yang signifikan 
daripada 1.89 (IQR, 0.53) kepada 1.60 (IQR, 0.25); p < 0.001. Perbezaan median INR yang 
lebih ketara bagi kumpulan yang merekodkan nilai pra transfusi INR melebihi 2.00 dan 
kumpulan yang menerima dos transfusi FFP antara 10.00 hingga 20.00 ml kg-1   (p < 0.001). 
Perbezaaan INR menunjukkan kolerasi yang signifikan dan positif dengan nilai pra 
transfusi INR (rs = 0.83, p < 0.001) dan dos FFP (rs = 0.72, p < 0.001). 
 
Kesimpulan: Prosedur intervensi selamat dijalankan walaupun tanpa normalisasi INR 
secara keseluruhan selepas transfusi (INR tidak normal). Transfusi profilaktik FFP sebelum 
prosedur intervensi boleh dielakkan bagi pesakit mengalami coagulopathy kurang teruk 
(INR 1.50 - 2.00). Risiko pendarahan boleh dikurangkan dengan bantuan kemahiran yang 
bagus dari doktor yang merawat.  
 
Kata kunci: transfusi profilaktik FFP, prosedur intervensi, international normalised ratio, 
dos FFP, coagulopathy 
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ABSTRACT 
  
Background: The fresh frozen plasma (FFP) is frequently prescribed by the clinicians 
either for therapeutic or prophylactic purpose. Prophylactic FFP transfusion in 
coagulopathic patient is given to prevent any bleeding complications during invasive 
procedures. The international normalised ratio (INR) value of 1.50 and above is frequently 
reported to be a transfusion trigger for FFP prior to interventional procedure. This study 
aims to evaluate the efficacy of FFP transfusion in normalising the INR prior to 
interventional procedures. On top of that, it is also to determine the post-transfusion 
outcomes (INR difference, bleeding episodes and adverse transfusion reactions).  
 
Methods: A prospective cross-sectional study involved 81 patients who received 
prophylactic FFP transfusion prior to interventional procedures over a period of three 
months (December 2016 until February 2017). The study was conducted at both Hospital 
Kuala Lumpur and Pusat Darah Negara. Study subjects with abnormal coagulation 
laboratory value (pretransfusion INR above 1.50) were selected by purposive (non-
probability) sampling. Data retrieved from patient’s medical record and were filled in the 
research proforma. All demographic and clinical data in regards to the outcome of FFP 
transfusion were captured. 
 
Results: The proportion of patients achieved posttransfusion INR below 1.51 was 30.30% 
(n=27) with one patient normalised to normal value (INR < 1.20).  Only two patients 
developed bleeding episodes post interventional procedure (one with major bleeding 
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episode and one with minor bleeding episode). The percentage of adverse transfusion 
reactions was low with 2.50%. The majority of patients underwent the interventional 
procedures with posttransfusion INR values of above 1.50 (n=52) without experiencing any 
bleeding episodes. Overall, FFP transfusion resulted in significant median difference of 
INR from 1.89 (IQR, 0.53) to 1.60 (IQR, 0.25); p < 0.001. The greater median INR 
difference was observed in group with pretransfusion INR above 2.00 and in group who 
received FFP doses between 10.00 to 20.00 ml kg-1 (p < 0.001). The INR difference 
showed the significant, positive correlation with pretransfusion INR values                        
(rs = 0.83, p < 0.001) and FFP doses (rs = 0.72, p < 0.001). 
 
Conclusions: The interventional procedures were safely carried out despite abnormal 
posttransfusion INR (uncorrected INR). The prophylactic FFP transfusions could be 
avoided in patients with mild coagulopathy (INR 1.50 - 2.00) prior interventional 
procedures. The risk of bleeding could be minimised by clinicians with the good 
techniques.  
 
Keywords: prophylactic FFP transfusion, interventional procedures, international 
normalised ratio, FFP doses, Coagulopathy. 
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CHAPTER 1- INTRODUCTION 
 
1.1 OVERVIEW 
 
1.1.1 Hospital Kuala Lumpur 
Hospital Kuala Lumpur (HKL) is a referral hospital with multi-disciplinary 
clinical departments and sub-specialties. HKL is considered the largest hospital governed 
by the Ministry of Health Malaysia (MOH) with the bed capacity of 2300 beds. As one 
of the leading centres in Malaysia, it receives referral cases from other hospitals, 
especially from the Klang Valley area. Multiple interventional procedures are performed 
within the facilities each day such as endoscopic retrograde pancreatography (ERCP), 
oral gastroduodenal endoscopy (OGDS), lower gastro intestinal endoscopy, 
bronchoscopy, central vein cannulations, femoral angiography, liver biopsy, kidney 
biopsy, lumbar puncture, paracentesis, thoracocentesis and drainage of an abscess. 
 
Pusat Darah Negara (PDN) is a blood centre located next to HKL. It is   
responsible for the planning and development of national blood transfusion services in 
Malaysia central region and for the national referral. The main services are to begin with 
blood donor selection, blood collection, blood components processing, laboratory testing 
and issuing blood components to government hospitals and private health centres in the 
Klang Valley area including HKL. PDN caters for supplying of blood and components 
preparation some government hospitals under Ministry of Health Malaysia (central 
region) such as Hospital Tengku Ampuan Rahimah Klang, Hospital Tuanku Jaafar 
Seremban, Hospital Temerloh, Hospital Putrajaya, Hospital Sungai Buloh, Hospital 
Selayang, Hospital Kajang and Institut Kanser Negara. 
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1.1.2 Fresh Frozen Plasma 
 
Fresh Frozen Plasma (FFP) is processed from whole blood collections and 
through plasmaphaeresis procedure. FFP prepared from whole blood collection is 
prepared within 8 hours and subsequently frozen at minus 18°C or below to preserve their 
coagulation factors activity as well as extend the shelf life. FFP contains normal 
coagulation factors, including the labile coagulation factors: factor (F) V, FVIII and other 
haemostasis proteins such as antithrombin and ADAMTS13. Each unit of FFP is about 
207 ± 51 ml from whole blood collection and 600 to 800 ml by plasmaphaeresis 
procedure (AABB Technical Manual, 2014). FFP has the shelf life up to 36 months if 
stored at colder than - 25°C and shelf life of three months if stored between -18 to -25°C 
(Europe, 2011). Once FFP is requested for transfusion, it is thawed at 30°C to 37°C in a 
waterbath to be able to transfuse clinically. For PDN, FFP is only stored at 2 to 6°C for 
24 hours post thawing. 
 
FFP is the commonly used blood components besides packed red cell and platelet 
concentrates in HKL. The National Transfusion Services report of 2013 to 2015 reported 
a total of 342,228 units of FFP were prepared and a total of 137,744 units were utilised 
nationwide. The Annual Report of PDN stated for the last 4 years from 2012 till 2015 
that HKL have received 9657 units, 7282 units, 7222 units and 7111 units respectively 
(Annual Report Blood Transfusion Services, 2015). 
 
1.1.3 FFP transfusion and its clinical indication 
FFP transfusion was prescribed by clinicians as either for therapeutic or 
prophylactic transfusion (Stanworth et al., 2011; Watson et al., 2011). FFP is known to 
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be effective in correcting multiple coagulation factor deficiencies such as in massive 
bleeding due to trauma and disseminated intravascular coagulation (DIC) due to many 
causes. In certain circumstances, FFP is also transfused to non-bleeding patients with 
coagulopathy to minimise the risk of bleeding as frequently seen in critically ill patients 
(Walsh et al., 2010).  
 
Coagulopathy is defined as an abnormal coagulation laboratory test such as 
prolonged prothrombin time (PT) or an elevation of international normalised ratio (INR). 
Early administration of FFP in patients with consumptive coagulopathy have proven to 
reduce the mortality rate and improved clinical outcomes especially in trauma cases 
(Brohi et al., 2003). However, a few studies reported that FFP transfusions were 
minimally effective in non-massively bleeding patients with mildly abnormal coagulation 
tests (Abdel-Wahab et al., 2006; Holland and Brooks et al., 2006).  
 
1.1.4 Pre interventional procedure of FFP transfusion and rationale to conduct the 
study 
 
Segal and Dzik (2005) described the three reasons for clinicians to prescribe FFP 
transfusion: (i) an elevation of the PT or INR as a prediction of bleeding risk, (ii) 
correction of prolonged or abnormal clotting time and (iii) reduction of overall bleeding 
events (Segal and Dzik, 2005). 
  
Patients in HKL were given FFP transfusions for bleeding causes as well as 
prophylaxis prior to a procedure. The prophylactic transfusion was given to patients with 
elevated INR (INR above 1.50) and expected to correct a targeted INR value prior to an 
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interventional procedure. The urgent interventional procedures are delayed in order to 
wait for an acceptable corrected INR value. Subsequently, the longer time required for 
pre-transfusion testing processes, including the delivery of blood products and a patient 
will expose too many episodes of blood transfusion before any intervention took place. 
The practice of prescribing FFP transfusion especially with mildly elevated INR need to 
be studied and recommendation for an evidence-based indication is necessary. 
 
Transfusion of FFP is not without a risk for adverse transfusion reaction. The 
common adverse transfusion reactions can be associated with FFP transfusion are allergic 
reaction, anaphylaxis reaction, febrile non-haemolytic transfusion reaction (FNHTR), 
transfusion associated circulatory overload (TACO), transfusion related acute lung injury 
(TRALI) and others. There was evidence that the adverse risk for prophylactic FFP 
transfusion may outweigh its clinical benefit, especially when the blood component was 
infused in haemodynamically stable patients with minimal prolongation of PT or INR 
(West et al., 2011). 
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1.2 RESEARCH JUSTIFICATION AND BENEFITS 
 
The FFP transfusion is a frequently prescribed by the clinician either for 
therapeutic or prophylactic purposes. The indication for FFP transfusion in coagulopathic 
patients was to prevent any bleeding complications when they scheduled for an invasive 
procedure (Stanworth et al., 2011; Watson et al., 2011).  
 
The good transfusion practice includes the right indication for each transfusion 
episode and appropriate use of FFP. This is crucial to ensure patient’s benefit is greater 
than having a transfusion risk. The clinician needs to identify patients with an elevated 
INR who may clinically benefit from receiving prophylactic FFP transfusions prior 
interventional procedure. Some patients with mild coagulopathy with hemodynamically 
stable (no bleeding) may not require the FFP coverage prior to the interventional 
procedure. 
 
The adequate dosage of FFP transfusion should be calculated according to body 
weight for an optimum haemostasis process. The recommended dose of FFP is between 
10.00 to 20.00 ml per kilogram body weight in each transfusion episode. The reduction 
of INR post-FFP transfusions was postulated in relation with volume FFP infusions. 
Inadequate volumes of FFP received by the patient (such as the patient with mild elevated 
INR or overweight patient) lead to minimal correction of the INR and higher chances for 
the second episode of FFP transfusion. Delaying undergoing procedures may jeopardise 
the treatment and management patient indirectly.  
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The FFP transfusion can be avoided for non-bleeding coagulopathy patients or 
mildly prolonged PT/INR patients and subsequently, they can undergo a procedure safely 
without any bleeding. Two previous studies demonstrated no significant risk of bleeding 
post central line insertions between patients with normal and abnormal coagulation      
tests (elevated INR or thrombocytopenia). The FFP transfusion to correct coagulation 
prophylactically was not necessary prior to central venous catheter insertion. It can be 
avoided in patients with pretransfusion INR values of up to 3.00 (Weigand et al., 2009; 
Carino et al., 2012). Minimising the use of FFP transfusions is crucial to reduce the risk 
of adverse transfusion events as stated earlier. A local study can be conducted to evaluate 
the outcome:  
i) Determine the cut off value of INR before the clinician decided that the 
FFP transfusion is required prior to an interventional procedure. 
ii) Reduction of INR value based on the recommended dose of 10.00 to 20.00 
ml per kilogram body weight per transfusion episode and pretransfusion 
INR value. 
iii) The number of adverse transfusion reactions associated with FFP 
transfusion and bleeding episode reported during or after the 
interventional procedure. 
 
The outcome of this study will contribute to a reduced use of FFP transfusions in 
correcting the INR value prior to an interventional procedure, and at the same time 
increase the awareness among clinicians regarding the judicious use of FFP. 
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1.3 LIST OF DEFINITIONS   
 
1.3.1 Fresh Frozen Plasma (FFP): A blood component either prepared from fresh 
whole blood collection or plasma collected by plasmaphaeresis. The FFP will be 
stored at an appropriate storage temperature to preserve the activity of coagulation 
factors (Transfusion Practice Guidelines, 2016). 
1.3.2 INR value of 1.50: The INR is an expression of the results of a PT in a 
standardized testing environment. It is calculated by using an international 
standard that corrects for laboratory variation. In the following calculation, the 
ISI is the International Sensitivity Index of the thromboplastin reagent used in the 
assay: INR = (patient PT/control PT)ISI (Malloy et al., 2009). INR value 1.50 was 
chosen based on the clinical practice and what is frequently reported to be the FFP 
transfusion threshold including for patients scheduled for any interventional or 
invasive procedures (Lauizer et al., 2007; Stanworth et al., 2011; Hall et al., 2012; 
Muller et al., 2015). 
1.3.3 Abnormal Coagulation Test: The coagulation test comprises measurements in 
vitro coagulation processes and the parameters of testing are the PT, INR and 
activated partial thromboplastin time (APTT). The abnormal coagulation test 
defined as an APTT is measured more than 38 seconds and/or INR is measured 
more than 1.20 or PT is prolonged more than 13 seconds (Abdel-Wahab et al., 
2006).  
1.3.4 Normalised prothrombin time and international normalised ratio: PT is less 
than 13 seconds and INR is less than 1.20 (Abdel-Wahab et al., 2006). 
1.3.5 Mild elevation of prothrombin time and international normalized ratio: The 
PT is less than 17 seconds or INR is less than 2.00 (Abdel-Wahab et al., 2006). 
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1.3.6 Fresh frozen plasma dose: The dose will be calculated by volume in millilitre 
(ml) divided to patient’s body weight in kilogram (kg) and ranged from           
10.00-20.00 ml FFP per kilogram for adult transfusions. 
1.3.7 Interventional procedures: endoscopic retrograde pancreotography (ERCP), 
oral gastroduodenal endoscopy (OGDS), lower gastrointestinal endoscopy, 
bronchoscopy, central vein cannulation, femoral angiography, liver biopsy, 
kidney biopsy, lumbar puncture, paracentesis, thoracocentesis and drainage of 
abscess (Muller et al., 2015). 
1.3.8 Bleeding episode in relation with the procedure: The bleeding episode 
categorised into major and minor bleeding. Major bleeding is deﬁned as bleeding 
associated with either:  
a) Haemoglobin reduction by more than 2 g/dL in the absence of another cause 
of bleeding. 
b) No increment of haemoglobin measurement after two or more units packed 
cells transfusion. 
Meanwhile, minor bleeding is deﬁned as any bleeding incidence at the site of 
insertion such as oozing or increase in the size of subcutaneous haematoma        
(Muller et al., 2015). 
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1.4 RESEARCH OBJECTIVES 
 
1.4.1 General Objective 
To evaluate the efficacy of FFP transfusion in normalising the INR prior to 
interventional procedures 
1.4.2 Specific Objectives 
i) To determine the percentage of INR ≤ 1.50 post-FFP transfusion. 
ii) To determine the transfusion outcomes ( INR difference, bleeding episode 
and adverse transfusion reaction) 
iii) To compare INR difference within the following groups : 
a) pretransfusion INR value 
b) FFP dose 
iv) To evaluate the correlation between INR difference and: 
a) pretransfusion INR value 
b) FFP dose 
 
1.5   Alternative Hypothesis 
i) There is a significant difference of median INR difference between groups of 
pretransfusion INR value and groups of FFP dose. 
 
ii) There is a positive correlation between the INR difference with pretransfusion 
INR value and FFP dose. 
 
10 
 
1.6   CONCEPTUAL FRAMEWORK    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The clinical practice of prophylactic FFP transfusion for INR normalisation 
prior to interventional procedures. 
Correcting the INR with 
FFP transfusion   
Coagulopathy, non-
bleeding patient requires 
interventional procedure   
INR > 1.50 
 
Posttransfusion INR is 
corrected or within 
acceptable value 
Independent factors: 
1) Pretransfusion 
INR value 
2) FFP volume and 
dosage  
3) Ongoing bleeding 
or blood loss  
 
Adverse transfusion event 
(acute or delayed onset)   
Bleeding outcome during 
or post interventional 
procedure  
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CHAPTER 2- LITERATURE REVIEW 
2.1  Preparation and clinical  guidelines of FFP  
 
FFP is one of the blood components collected from whole blood donation or by 
aphaeresis blood donation. It should be processed within 8 hours after blood collection 
by using the specific blood centrifuge machine. In PDN, if whole blood collected from 
the double bag, it will undergo hard spin centrifugation to separate red cells from plasma. 
Meanwhile, the triple bag whole blood unit will undergo soft spin in order to separate red 
cells from platelet rich plasma (PRP). PRP will be processed to separate FFP and platelet 
concentrate by using hard spin centrifugation at 20 to 24 °C. Following that, the processed 
FFP is frozen using the blast freezer and is stored at minus 18°C or below. This is 
necessary to preserve all the coagulation factors, including the labile coagulations factors 
such as factors V and VIII. Most FFP units contain 225 ± 25 ml from single whole blood 
donation and plasmaphaeresis derived units may contain up to 600 ml in volume 
(Labarinas et al., 2013). Upon request, FFP needs to be thawed for 15 to 30 minutes at 
37°C for clinical usage. The thawed FFP has the shelf life of 24 hours if kept at 2 to 6 °C.    
In addition, in United State, it can be stored for another 4 days if stored at 2 to 6 °C and 
labelled as Thawed Plasma (AABB Technical Manual, 2014). 
   
After thawing, FFP will contain almost near normal levels of pro-coagulant 
plasma protein, inhibitory protein of the coagulation system, immunoglobulin, albumin 
and others acute phase proteins. Prior blood administration, the transfusion services    
must ensure the FFP should be safe and meet the standard production quality                       
set by international and national requirement. The standard FFP with the volume of 200         
to 250 ml contain at least 0.7 IU/ml of factor VIII in at least 75% of the FFP units       
12 
 
(O’Shaughnessy et al., 2004). In line with United Kingdom guideline, PDN quality 
control requirement for factor VIII level is more than 0.7 IU/ml and 10 units FFP tested 
in every 3 months (Transfusion Practice Guidelines, 2016). FFP transfusion for surgical 
and traumatic bleeding should be guided by coagulation testing. 
 
The usage of FFP has grown steadily over past two decades in the United 
Kingdom. Prophylactic FFP transfusion accounts for almost 50% and was given prior an 
invasive procedure or surgery (Stanworth et al., 2011). There was a local guideline 
available regarding the indications of FFP transfusion. The FFP can be transfused for the 
immediate reversal of overwarfarinisation in the presence of potentially life-threatening 
bleeding, if the prothrombin factor concentrate (PCC) is not available. It is clinically used 
for the treatment of multiple coagulation factor deficiencies associated with acute 
bleeding in disseminated intravascular coagulation (DIC) and abnormal coagulation 
parameters following  cardiac bypass surgery, massive transfusion or in patient with liver 
disease (Rational Use of Blood and Blood Products, 2007). Multiple international 
guidelines proposed the FFP transfusion can be considered prior to invasive procedure or 
surgery in patient with clinical coagulopathy. The cut off value for FFP transfusion was 
PT greater than 1.5 times the midpoint of the normal range (usually >18 seconds or INR 
1.5) or aPTT greater than 1.5 times the top of the normal range (Fresh-Frozen Plasma, 
Cryoprecipitate, and Platelets Administration Practice Guidelines, 1994; Liumbruno        
et al., 2009; Michelle et al., 2007; Blood transfusion: summary of NICE guidance , 2015). 
 
Besides, FFP also can be used to treat for single factor deficiency when specific 
human plasma based or recombinant factor concentrate is unavailable. It is be used to 
treat the bleeding or as the prophylactic infusion in the patient with underlying factor II, 
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V, XI, XIII, Fibrinogen and Protein C deficiency (Benjamin and McLaughlin, 2012). 
Blombery and Scully (2014) suggested the plasma exchange is the first line treatment for 
thrombotic thrombocytopenic purpura. It will provide the source of ADAMTS 13 protein 
and the autoantibody in blood circulation will remove via plasma exchange (Blombery 
and Scully, 2014). Early administration of FFP in trauma patient resuscitation will 
prevent the early-trauma induced coagulopathy and increased initial survival rate with 
higher ratio packed cells: FFP transfusion (Mitra et al., 2010). 
 
The effects of FFP transfusion were more beneficial in the correction of multiple 
clotting factor deficiencies such as massive bleeding and consumptive coagulopathy such 
bleeding DIC (O’Shaughnessy et al., 2004). A few studies reported that FFP was also 
frequently administered prophylactically in critical illness, non-bleeding patients with 
coagulopathy as evidenced by prolonged PT or elevated INR (Dara et al., 2005; Lauzier 
et al., 2007; Vlaar et al., 2009; Tinmouth et al., 2013). In a prospective study conducted 
by Stanworth et al in 2011, about 15% of FFP transfusions (out of 388 treatment episodes) 
were given to non-bleeding patients prophylactically prior to undergoing any procedures 
(Stanworth et al., 2011). 
 
Despite multiple guidelines regarding the clinical indication of FFP published, 
there were variable percentages of FFP appropriateness or misused FFP usage based on 
their local clinical transfusion guidelines (Yang et al., 2012). A study conducted in 
Singapore by Chng et al. (2003) showed only 27% transfusion episodes were deemed 
appropriate and 73% of inappropriate requests (such as non-bleeding DIC and INR ≤ 1.50 
without any bleeding episode) were similar across clinical specialties (Chng et al., 2003). 
Stanworth et al. (2011) reported in the United Kingdom, 43% of FFP transfusions were 
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given to the non-bleeding patient and as prophylactic transfusion prior procedures or 
surgery for both adults and children. About 56% of plasma was transfused to reverse the 
overwarfarinisation without any underlying bleeding. For FFP dosing, they found 40% 
of adults, 24% of children and 20% of infants were transfused with FFP dose of less than 
10.00 ml kg-1 (Stanworth et al., 2011). Meanwhile, an audit study of FFP utilisation in 
Canada found 28.6% were inappropriate transfusions as FFP were administered to 
patients with an INR below 1.50 and in the absence of bleeding (Tinmouth et al., 2013). 
A prospective study was conducted among 100 patients who received FFP transfusions 
from June 2013 to June 2014 at Vinayaka Mission’s Kirupananda Variyar Medical 
College & Hospital. They found 74% transfusion episodes were appropriate based on 
National Health And Medical Research Council and the Australasian Society for Blood 
Transfusion fresh frozen plasma (Jayanthi and Pitchai, 2015). Another recent study 
conducted by Alcon et al. (2017), compliance of FFP transfusion based on institution-
specific guidelines was at the higher rate (90% of 3018 transfusion events) (Alcon et al., 
2017). Pratiba et al. (2001) retrospectively analysed on the practice of FFP transfusions 
in the University Hospital, Kuala Lumpur. The authors have found that 60% of the total 
FFP units were inappropriately transfused across the multiple clinical departments. The 
causes of inappropriate FFP usage were as a volume expansion, no coagulation blood 
testing available prior to transfusion, INR less than 1.5 and in cardiac-bypass surgery post 
operative bleeding (Pratiba et al., 2001). 
 
2.2  Correcting the INR with FFP transfusion  
 
There were studies that reported on the effectiveness of FFP transfusions on 
normalising the INR in the hospitalised coagulopathy patient. The INR of at least 1.50 
15 
 
was frequently reported to be the transfusions trigger for prophylactic FFP transfusion 
prior procedures (Lauzier et al., 2007; Stanworth et al., 2011; Hall et al., 2012 and Muller 
et al., 2015). Muller et al. (2015) conducted a multicentre randomised control trial (RCT) 
in the Netherlands on prophylactic FFP transfusion. The selected study subject was 
critically ill patients with coagulopathy (INR 1.50 to 3.00) underwent an invasive 
procedure. However, the clinical trial was terminated early due to slow inclusion of study 
subjects. Even though the prophylactic FFP transfusion resulted in a reduction of INR, 
only 54% of transfused patients had a corrected INR of less than 1.50. The efficacy of 
FFP transfusion on INR normalisation varied widely. Patients with the higher 
pretransfusion INR values recorded the largest INR difference (r = 0.68, p < 0.01). Their 
findings showed an INR reduction posttransfusion and however, it was not a complete 
normalisation of INR after FFP transfusion (Muller et al., 2015). 
 
 
In a prospective audit of all FFP transfusions at the Massachusetts General 
Hospital (September 2004 until September 2005), Abdul-Wahab et al. (2006) analysed 
121 patients with mild coagulopathy (INR ≤ 1.85). FFP transfusion resulted in the 
normalisation of posttransfusion PT/INR in only 0.8% of patients and decreased the 
PT/INR halfway toward normal values in only 15% of patients. The median INR 
difference was 0.07 post-FFP transfusion. The authors found no significant relationship 
between pretransfusion PT value and 50% correction of the PT post-FFP transfusion. A 
minority of patient achieved partial normalisation of posttransfusion PT with 99% of 
study subject recorded uncorrected PT post-FFP transfusion (Abdul-Wahab et al., 2006). 
 
A retrospective cohort study was done by Dara et al. (2005) on the effectiveness 
of FFP transfusion in the critically ill patient with coagulopathy. They found that the INR 
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was corrected to less than 1.50 in only 36% of patients (16 out 44 patients with median 
pretransfusion INR 2.70) post-FFP transfusion. The risk-benefit ratio of FFP transfusion 
in critically ill medical patients with mild coagulopathy may not be favourable             
(Dara et al., 2005). The subsequent year, Holland and Brooks (2006), reported that FFP 
treatments were minimally effective in correcting mild elevation in INR (INR less than 
1.70). There were significant changes in the posttransfusion INR values if pretransfusion 
INR above than 1.70. The authors concluded that minimally elevated INR cannot be 
corrected with FFP administration at currently accepted dosages and INR normalisation 
was correlated with the pretransfusion INR value (Holland and Brooks, 2006). 
 
2.3  Association between posttransfusion INR values with FFP dose. 
 
There was an association between the volume and doses of FFP with reduction 
values of posttransfusion INR. In a small cohort study of 22 critically ill patients, a dose 
of 33.00 ml kg-1 was more effective in achieving target levels of coagulation factors 
compared to 12.00 ml kg-1 (Chowdhury et al., 2004). Dara et al., (2005) retrospectively 
reported the median dose of FFP was higher in the group (17.00 ml kg-1 vs                      
10.00 ml kg-1 with p-value 0.018) whose INR decreased to 1.50 post-transfusion          
(Dara et al., 2005). However, a multicentre RCT done in Netherlands found that the INR 
was partially corrected with a dose of 12.00 ml kg-1 in patients with coagulopathy    
(Muller et al., 2015).  
 
Hall et al. (2012) evaluated the FFP dose with reduction of INR post transfusion. 
This was a prospective cohort among patients with coagulopathy who underwent  
vascular catheterisation. They found more than half of patients received FFP dose less 
than 10.00 ml kg-1, which was unlikely to reliably correct coagulation factor defects   
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(Hall et al., 2012). A multicentre, prospective observational study by Stanworth et al. 
(2011) concluded the posttransfusion corrections of INR in critical care patients were 
consistently small unless the pretransfusion INR value greater than 2.50. The median 
volume FFP given prior to the invasive procedure was 560 ml and the median FFP dose 
given was 9.80 ml kg-1. In relation to the FFP dose and pretransfusion INR value, the 
authors confirmed there was a larger dose given for higher pretransfusion INR value in 
order to achieve targeted posttransfusion INR value. The median reductions in 
posttransfusion INR were greater when the pre-FFP transfusion values were higher. There 
was no significant relationship between the degree of change of INR and dose of FFP 
used with a p-value of 0.86 (Stanworth et al., 2011).  
   
2.4  Bleeding outcome   
 
Bleeding is a common complication during and after any interventional 
procedure. The risk of bleeding is greater in patients with coagulopathy. Numerous 
retrospective studies reported the low incidence (less than 1%) of major bleeding after  
an invasive procedure in patients with a prolonged INR (Mumtaz et al., 2000;                    
Fisher et al., 1999; Goldfarb et al., 1982). A multicentre RCT was done by Muller et al. 
(2015) found occurrences of bleeding complications after an invasive procedure did not 
differ between transfused and non-transfused patients. There were six patients in the non-
transfused group had bleeding episode compared to eight patients in the FFP group with                        
p-value 0.77. They suggested the invasive procedures can be safely carried out without 
prophylactic FFP transfusion (Muller et al., 2015). 
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Foster et al. (1992) reported 202 percutaneous central venous catheter insertions 
performed in patients with coagulopathy without any major bleeding episodes. The INR 
values more than 5.00 (n = 137) or platelet counts less than 50,000/μL (n = 146) was 
associated with a higher incidence of superficial hematomas or site oozing, respectively 
(Foster et al., 1992). Another study by Fisher et al. (1999) reported 658 central venous 
cannulations in patients with advanced liver disease and coagulopathy. The median INR 
was 2.40 (range: 1.00 - 16.00) and the median platelet count was 81,000/μL (range: 9000 
to 1,088,000/μL). Preprocedure FFP or platelets transfusions were not administered 
routinely. They found only one patient had bleeding complications (superficial skin 
hematomas and mild oozing at the puncture site) attributed to the technical mishap. This 
paper reveals that technical mishaps remain the main contributing factors for haematoma 
formation. Others bleeding complications are rare regardless of the coagulation test 
results (Fisher et al., 1999). 
 
A retrospective study was done at the University of Pennsylvania Medical Center       
on the outcomes of 567 central venous catheterisations. The procedures were carried out 
in patients with platelet counts below 50,000/μL and/or an INR > 1.50. There were no 
haemorrhagic complications occur in the group with abnormal laboratory parameters. 
Meanwhile, three bleeding complications (1 in 1057) reported even with platelet counts 
above 50,000/μL and INR < 1.50. Despite these very abnormal laboratory test results, the 
complication rate in this group with abnormal laboratory results (without correction by 
plasma infusion) was identical to that of patients with more normal laboratory numbers 
(Haas et al., 2010). The subsequent study by Carino et al. (2012) showed no benefits of 
prophylactic FFP observed in a retrospective cohort study in patients with post central 
line insertion. Out of 27 transfused patients, only one patient with INR 3.90 had a 
bleeding episode post-procedure. The occurrence of bleeding episodes post central line 
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insertion was 0.03% in both transfused and non-transfused patients. The results suggested 
that the prophylactic plasma transfusion can be avoided when the INR is less than 3.00 
and used highly selectively in patients with higher INR values (Carino et al., 2012). 
 
 A prospective study conducted by Mac Donald et al. (2003) evaluated ten 
patients with end-stage liver disease (INR above 1.50) underwent cardiac catheterisation. 
Only one patient developing a haematoma post-procedure. The retrospective studies 
suggested that commonly performed invasive procedures in the critically ill, such as 
thoracocentesis, central venous catheter insertion and percutaneous tracheostomy, carry 
a low bleeding risk (Segal and Dzik, 2005; Hibbert et al., 2013; Rosseland et al., 2011). 
Hibbert et al. (2013) conducted a retrospective study to assess haemorrhagic 
complications post ultrasound-guided thoracentesis. They found only 0.4% out of 1009 
patients have haemorrhagic complication post-procedure. All patients with haemorrhagic 
complications had received FFP transfusion prior to the procedure. The haemorrhagic 
complications were infrequent and attempting to correct abnormal INR or platelet level 
before the procedure was unlikely to confer any benefit (Hibbert et al., 2013). In the 
earlier study done in 1991 by McVay and Toy showed no significant risk of bleeding in 
mild coagulopathy patients compared to normal patients. Apart from that, they reported          
the overall frequency of clinically significant bleeding complications was very low         
(0.2%, 1/608 events). The prophylactic blood component transfusion was not 
recommended for paracentesis and thoracentesis in non-bleeding patients with mild 
coagulopathy (McVay and Toy, 1991).  
 
In a prospective study by Makris et al. (1992) evaluated the bleeding incidences 
for 104 patients underwent liver biopsy. The INR, aPTT, thrombin time, fibrinogen, 
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bleeding time, and platelet count were measured before the procedure. More than half of 
patients recorded one or more abnormalities of laboratory testing results. The highest INR 
value was 2.00 and platelet counts were above than 50,000/μL. They reported two 
patients experienced procedure-related bleeding and eventually, both of patients had 
normal pre-procedure coagulation parameters (Makris et al., 1992). Diette et al. (1999) 
reported a retrospective review of 720 fiberoptic bronchoscopies performed over a 12-
month period at Johns Hopkins Hospital. They concluded that bleeding complications 
were poorly correlated with coagulation parameters or platelet count. On top of that, 
transbronchial biopsy can be safely performed without an increase the risk of bleeding                         
(Diette et al., 1999). 
 
2.5 Complications of FFP transfusion 
 
The FFP transfusion carries a risk for adverse transfusion reactions. It can cause 
morbidity and mortality to the recipient. Plasma transfusion complication can be either 
divided as acute or delayed transfusion reactions. Others classification, It also can be 
divided into infectious or non-infectious transfusion complications. Acute transfusion 
reaction occurs less than 24 hours from the onset of transfusion (AABB Technical 
Manual, 2014). Among the transfusion reactions for plasma were include TRALI, TACO, 
allergic/ anaphylaxis reactions, FNHTR, post transfusion purpura (PTP) and transfusion-
associated graft versus host disease (TA-GVHD). As for other complications, plasma 
transfusion reported having a higher risk to develop multiple organ failures (2.1% 
increases for every FFP unit transfusion) and acute respiratory distress (2.5% increases 
for every unit of FFP) (Watson et al., 2009). As such, clinical justification of FFP 
transfusion of whether the benefit is far greater than the risk of any adverse transfusion 
reactions is very crucial. 
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An allergic or anaphylactic reaction is commonly associated with FFP and platelet 
transfusions with percentages of  80% and 60% out of the total allergic/anaphylaxis 
incidences respectively, reported in the year 2015 (Serious Hazards of Transfusion 
Annual Report, 2015). The incidence of allergic transfusion reactions has been estimated 
less than 3% of all transfusions with most of them presented with mild symptoms such 
as to urticaria, pruritus and/or flushing (Domen et al., 2003; Vamvakas et al., 2007). 
Meanwhile, Karim et al. (2014) reported allergic reaction was one of the most common        
adverse transfusion reaction accounting for 57.8% of all transfusion reactions                             
(Karim et al., 2014). It is due to the presence of plasma allergens such as IgA and 
haptoglobin. A patient may experience urticaria, pruritus, facial puffiness, and               
oral-pharyngeal oedema. In severe form of allergic reactions, patient may experience 
hypotension, bronchospasm and stridor. Pretransfusion medication with antipyretics and 
antihistamine are widely used to prevent this reaction. In the patient who has the 
deficiency in IgA (serum IgA < 0.5 mg/L) or haptoglobin, transfusion with IgA free 
plasma components are necessary to reduce the risk of severe allergy transfusion reaction   
(Hirayama, 2012). The incidences of anaphylaxis secondary to plasma transfusion are 
very uncommon and happened in only 1% to 3% of total plasma transfusions 
(O’Shaughnessy et al., 2004).    
 
Apart from allergy, FNHTR is another most commonly encountered transfusion 
reaction. Usually, it is mild in severity, self-limiting and documented fever more            
than 1°C increment from baseline body temperature, chills, and rigors. The mechanism 
involved in FNHTR is recipient’s anti-leukocyte antibody that is directed against    
donor’s HLA antigen, or against granulocyte-specific antigen and due to the 
accumulation of cytokines in the blood components (Arewa, 2012). Universal 
22 
 
leukoreduction or leucodepletion of RBCs had proven to reduce the incidence of FNHTR 
from 0.37% to 0.19% (King et al., 2004). FFP administration is associated with acute 
lung injury and the incidence increased up to 30% of transfused critically ill patients 
(Dara et al., 2005). Sarani et al. (2008) reported retrospectively that FFP transfusion was 
associated with increased risk of infectious complications such as ventilator associated 
pneumonia and bacteraemia shock in critically ill patients (Sarani et al., 2008). 
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CHAPTER 3 – MATERIALS AND METHODS 
 
3.1 INTRODUCTION 
  
HKL is the biggest tertiary hospital in Malaysia. HKL has various facilities and a 
substantial number of clinical experts in various specialties and sub specialties. Hence, 
numerous interventional procedures carried out by many disciplines in the hospital.  
 
 
Among all patients that were scheduled for interventional procedures,                        
a proportion of them were having abnormal coagulation profiles secondary to the 
underlying medical diseases. These patients may require the FFP transfusion as a 
precautionary measure to minimise bleeding complications during or after the procedure.  
 
3.2 STUDY DESIGN 
 
This prospective cross-sectional study was composed of data from 81 patients 
who received FFP transfusions prior to interventional procedures within the data 
collection period.  
 
 3.3 PERIOD OF STUDY 
 
This study was conducted at both PDN and HKL. The period of study was from 
1st June 2016 until 31st March 2017. The period of data collection started from December 
2016 to February 2017. 
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3.4 SAMPLING METHOD 
Study cases were chosen using purposive (non-probability) sampling according 
to the inclusion and exclusion criteria stated in section 3.7. 
 
3.5 STUDY POPULATION 
 
Our source population were all patients with abnormal coagulation laboratory 
values (INR above 1.50) and received FFP transfusions from December 2016 until 
February 2017. Then, the patient underwent the interventional procedure post-FFP 
transfusion as part of the clinical management. The study cases were selected based on 
the inclusion and exclusion criteria. The sample size calculation is as shown in           
section 3.6. 
 
3.6 SAMPLE SIZE  
 
The sample size was calculated using a computer software, PS: Power and Sample 
Size Calculation version 3.0, 2009 (Dupont and Plummer, 1997). The sample size 
estimation based on RCT by Muller et al. (2015); only 54% of patients had a corrected 
INR to less than 1.50 in 38 patients who underwent the interventional procedure. The 
study precision was set to be 12% with 95% confidence interval (CI) and 0.54 of study 
proportion. The estimated sample size was to be 67 subjects.  
 
For the correlation of pretransfusion INR with median INR reduction 
posttransfusion, the sample size was calculated based on the study done by                  
Muller et al. (2015), with the r = 0.68 and a p-value less than 0.01. The correlation sample 
size estimation was calculated based on the correlation sample from the computer 
